https://www.gjpb.de/index.php/gjpb/issue/feed German Journal of Pharmaceuticals and Biomaterials 2022-06-30T05:33:46-04:00 Open Journal Systems <p style="text-align: justify;"><strong>German Journal of Pharmaceuticals and Biomaterials (GJPB) [ p-ISSN: 2750-624X | e-ISSN:2750-6258 ] </strong>is an interdisciplinary peer reviewed open access scientific journal, publishes high-quality experimental and theoretical research that contributes significantly on all aspects of pharmaceutical sciences and biomaterials and their related subjects including their applications in human (covering experimental and clinical therapeutics). The mission is to publish scientific work that has followed laborious methodologies and to contribute to progress and development in both pharmaceuticals and biomaterials. <br />Scientific areas within the scope of this journal include but are not limited to pharmaceutics (all aspects of formulations and drug delivery systems, including oral, pulmonary, nasal, parenteral and transdermal delivery) and biopharmaceutics, including pharmaceutical biotechnology products, biochemistry and microbiology, pharmacology and toxicology, applied separation science (covers all areas of analytical/chromatography techniques), natural product drug discovery, medicinal chemistry, and bioactive polymers. This journal is also interested in work that addresses biomaterials but is not limited to covering all aspects of biomaterials with broad range of physical, biological and chemical sciences that support the design of biomaterials and the clinical/scientific disciplines in which they are used.</p> <p style="text-align: justify;"><strong>Country of Publication:</strong> Germany<br /><strong>Frequency:</strong> Quarterly (4 issues/year)</p> https://www.gjpb.de/index.php/gjpb/article/view/27 The Applications of food hydrocolloids in drug delivery system 2022-05-27T13:53:58-04:00 Javeria Tamkeen javeriatamkeen9@gmail.com Latha Kukatil lathakukatil@gmail.com Aisha Rahman aisharahman.ar17@gmail.com Padmavathi Reddi rpvathi79@gmail.com Sai Pavani Gundlapalli gundlapallipavani@gmail.com <p>Food hydrocolloids are multifunctional natural substances that are being exploited to create a new generation of functional foods that improve health and well-being. Pharmaceutical and culinary formulations play a crucial role in rheology, tribology, and intuition. According to current research, hydrocolloids have the potential to tailor nutritional value and deliver therapeutic benefits by lowering plasma cholesterol, postprandial glucose, glycemic response, insulin secretion, and preventing colon cancer by controlling meal transit, digestion, and gastric emptying. They also enhance the bioavailability of specific bioactive moieties and drugs by delivering them to the gastrointestinal tract in a regulated and targeted manner. The use of food hydrocolloids, particularly proteins and polysaccharides, as viscosity modifiers, gelling, coating, stabilizing agents, and emulsifiers in the drug delivery system and the nutraceutical potential utility of food colloids as functional components, are discussed in this article.</p> 2022-06-30T00:00:00-04:00 Copyright (c) 2022 Javeria Tamkeen, Latha Kukati, Aisha Rahman, Padmavathi Reddi, Sai Pavani Gundlapalli https://www.gjpb.de/index.php/gjpb/article/view/52 Machine learning empowered drug discovery 2022-06-30T04:49:09-04:00 Thirumoorthy Durai Ananda Kumar anandurai78@gmail.com Naraparaju Swathi swa.pharma@gmail.com <p>Traditional drug discovery strategies include lead molecule identification, lead optimization, preclinical studies and clinical trials. The pharmaceutical and biotechnology research and development (R&amp;D) department spends more than 10 years and $1 billion to bring the molecule to market successfully. About 90% of drug candidates fail in the drug development due to safety and efficacy issues. The lack of technologies is the main limitation for identifying potential candidates from the available chemical space (&gt;1060 molecules).<br>De Novo design methods explore chemical space through pharmacophore (ligand-based), and docking (structure-based) approaches. Structure-based drug discovery approaches use the insights gained from biological data of target structures. Schrödinger, AutoDock and Biovia (Accelrys) pioneered the development of structure-based tools to improve drug discovery. Libraries of molecules can be screened for their target suitability, known as virtual screening. The structure-based drug discovery approach uses the three-dimensional (3D) details of the target structure and explains the intermolecular interactions (biophysical simulations). Ligand-based drug discovery approaches are based. Read more.........</p> 2022-06-30T00:00:00-04:00 Copyright (c) 2022 Authors https://www.gjpb.de/index.php/gjpb/article/view/36 Antimicrobial activities of Nardostachys jatamansi extract against multidrug resistant bacterial species 2022-06-09T05:04:43-04:00 Piyali Karmakar karmakarpiyali2000@gmail.com Sayan Paul sayansubho17021998@gmail.com Bhaskar Narayan Chaudhuri bhaskarnchau@gmail.com Partha Guchhait drparthaguchhait5@gmail.com Satadal Das drsatdas@hotmail.com <p>At present, multidrug resistant (MDR) bacteria have become widespread worldwide, leading to high morbidity and mortality rates in bacterial infections. Again, as there is practically no new antimicrobial agent in the pipeline, this will create a threat to humanity for their survival. In this study, we explored the possible antimicrobial action of ethanolic extract of a typical plant of West Bengal, <em>Nardostachys jatamansi</em>, against MDR and American Type Culture Collection (ATCC) strain bacteria. Antimicrobial activities of <em>Nardostachys jatamansi</em> ethanol extract were studied by disc diffusion technique, and then minimum inhibitory concentration (MIC) determination was done by serial dilution in Mueller Hinton broth. Ethanolic extract of <em>Nardostachys jatamansi</em> showed antimicrobial activities with MIC varied between 2.77- 5.82 mg/mL in both MDR and ATCC bacteria. Ethanolic extract of <em>Nardostachys jatamansi</em> is an effective antimicrobial agent on MDR bacteria and may help save the lives of many critically ill patients.</p> 2022-06-30T00:00:00-04:00 Copyright (c) 2022 Authors https://www.gjpb.de/index.php/gjpb/article/view/54 Front matter 2022-06-30T04:58:42-04:00 Editor editor@gjpb.de <p>Front matter&nbsp;</p> 2022-06-30T00:00:00-04:00 Copyright (c) 2022 https://www.gjpb.de/index.php/gjpb/article/view/37 The outcome of a recent online survey carried out in India on self-reported adverse events following COVID-19 vaccination 2022-06-01T11:54:08-04:00 Smita Nayak smitanayak125@yahoo.com Ashish Babtiwale ashish.b@navigoanalytix.com Hemangi Padhye padhyehemangi@gmail.com Bhaskar Vaidhun vhbhaskar@gmail.com <p><span style="font-size: 0.875rem;">The last two years have been mainly in the grip of the coronavirus pandemic. In record time, the healthcare sector has worked tirelessly to introduce the COVID-19 vaccines. As the pandemic continues to rage, the pace of vaccination is being increased to reduce the aftermath of the destruction caused by the virus. Information about the adverse events experienced post-vaccination will help further improve vaccines. The objective of this study was to collect data on adverse events experienced following COVID-19 vaccination in India to assess these vaccines' tolerability and apparent safety. In order to analyse adverse effects post-vaccination, a questionnaire was developed for an online survey. A pilot was carried out and posted online. Responses from 722 respondents were collected between May 2021 to December 2021 and analysed with the help of excel analytics and statistics in a scientific manner. The survey revealed that less than 50% of the vaccinated respondents </span><span style="font-size: 0.875rem;">experienced adverse effects after the first dose of COVID vaccines. Perceived side effects included pain, redness, swelling, headache, body ache, muscle pain, joint pain, tiredness, lethargy, chills, fever, nausea, giddiness, and diarrhoea. Less than 1% of the respondents were reportedly hospitalized for alleviation of their symptoms post-vaccination (first and second doses). The rest recovered from the side effects with none to minimal treatment on an outpatient basis. The vaccines under study elicited side effects in less than 50% of the respondents and were well-tolerated overall.s and were well-tolerated overall.</span></p> 2022-06-30T00:00:00-04:00 Copyright (c) 2022 Authors